DK2374461T3 - Piroxicam for the prophylactic and therapeutic treatment of herpes infections - Google Patents
Piroxicam for the prophylactic and therapeutic treatment of herpes infections Download PDFInfo
- Publication number
- DK2374461T3 DK2374461T3 DK11001816.5T DK11001816T DK2374461T3 DK 2374461 T3 DK2374461 T3 DK 2374461T3 DK 11001816 T DK11001816 T DK 11001816T DK 2374461 T3 DK2374461 T3 DK 2374461T3
- Authority
- DK
- Denmark
- Prior art keywords
- agent
- virus
- prophylactic
- herpes
- therapeutic treatment
- Prior art date
Links
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 title claims description 17
- 229960002702 piroxicam Drugs 0.000 title claims description 15
- 230000001225 therapeutic effect Effects 0.000 title claims description 11
- 230000000069 prophylactic effect Effects 0.000 title claims description 10
- 206010019973 Herpes virus infection Diseases 0.000 title description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 241001529453 unidentified herpesvirus Species 0.000 claims description 12
- 230000009385 viral infection Effects 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 6
- 208000009889 Herpes Simplex Diseases 0.000 claims description 5
- 208000004898 Herpes Labialis Diseases 0.000 claims description 4
- 206010067152 Oral herpes Diseases 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 229940098465 tincture Drugs 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims 8
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 208000010201 Exanthema Diseases 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 201000005884 exanthem Diseases 0.000 description 6
- 206010037844 rash Diseases 0.000 description 6
- 208000007514 Herpes zoster Diseases 0.000 description 5
- 229960001259 diclofenac Drugs 0.000 description 5
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960004752 ketorolac Drugs 0.000 description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000003253 viricidal effect Effects 0.000 description 2
- 229940124638 COX inhibitor Drugs 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical group N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940065410 feldene Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000010531 varicella zoster infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010014290A DE102010014290A1 (de) | 2010-04-08 | 2010-04-08 | Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2374461T3 true DK2374461T3 (en) | 2017-02-06 |
Family
ID=43970974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11001816.5T DK2374461T3 (en) | 2010-04-08 | 2011-03-04 | Piroxicam for the prophylactic and therapeutic treatment of herpes infections |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20130190301A1 (enExample) |
| EP (1) | EP2374461B1 (enExample) |
| JP (1) | JP6158077B6 (enExample) |
| CN (1) | CN103153312B (enExample) |
| CA (1) | CA2795334C (enExample) |
| DE (1) | DE102010014290A1 (enExample) |
| DK (1) | DK2374461T3 (enExample) |
| ES (1) | ES2612584T3 (enExample) |
| PL (1) | PL2374461T3 (enExample) |
| RU (1) | RU2555765C2 (enExample) |
| WO (1) | WO2011124366A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010014290A1 (de) * | 2010-04-08 | 2011-10-13 | Hans Otto Meyer zu Spelbrink | Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen |
| DE102013003756A1 (de) | 2013-03-06 | 2014-09-11 | DeaValorum UG (haftungsbeschränkt) | Piroxicam zur prophylaktischen und therapeutischen Behandlung von CMV-Infektionen |
| DE102013014787A1 (de) | 2013-09-09 | 2015-03-12 | Dauphine UG (haftungsbeschränkt) | Mittel zur prophylaktischen und therapeutischen Behandlung von EHV-Infektionen |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3437232A1 (de) * | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
| IT1216686B (it) * | 1988-04-01 | 1990-03-08 | Chiesi Farma Spa | Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione. |
| IT1230922B (it) * | 1989-06-23 | 1991-11-08 | Giuseppe De Benedittis | Composizione per il trattamento della nevralgia erpetica acuta e della nevralgia post erpetica |
| ATE95421T1 (de) * | 1990-04-26 | 1993-10-15 | Sagitta Arzneimittel Gmbh | Piroxicam enthaltende pharmazeutische zusammensetzung zur topischen anwendung. |
| JP3031990B2 (ja) * | 1990-10-19 | 2000-04-10 | 同仁医薬化工株式会社 | 消炎鎮痛クリーム剤組成物 |
| RU2182016C2 (ru) * | 1997-03-20 | 2002-05-10 | Панацея Биотек Лтд. | Спазмолитическая композиция, способ получения спазмолитической композиции |
| DE10300222A1 (de) * | 2003-01-03 | 2004-07-15 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen |
| US7132452B2 (en) | 2003-03-10 | 2006-11-07 | Fang-Yu Lee | Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection |
| DE102010014290A1 (de) * | 2010-04-08 | 2011-10-13 | Hans Otto Meyer zu Spelbrink | Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen |
-
2010
- 2010-04-08 DE DE102010014290A patent/DE102010014290A1/de not_active Ceased
-
2011
- 2011-03-04 EP EP11001816.5A patent/EP2374461B1/de active Active
- 2011-03-04 ES ES11001816.5T patent/ES2612584T3/es active Active
- 2011-03-04 DK DK11001816.5T patent/DK2374461T3/en active
- 2011-03-04 PL PL11001816T patent/PL2374461T3/pl unknown
- 2011-04-06 RU RU2012147474/15A patent/RU2555765C2/ru active
- 2011-04-06 CN CN201180021384.XA patent/CN103153312B/zh not_active Expired - Fee Related
- 2011-04-06 WO PCT/EP2011/001704 patent/WO2011124366A1/de not_active Ceased
- 2011-04-06 CA CA2795334A patent/CA2795334C/en active Active
- 2011-04-06 US US13/639,357 patent/US20130190301A1/en not_active Abandoned
- 2011-04-06 JP JP2013503032A patent/JP6158077B6/ja not_active Expired - Fee Related
-
2014
- 2014-01-29 US US14/167,676 patent/US20140148447A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2795334C (en) | 2015-06-09 |
| US20140148447A1 (en) | 2014-05-29 |
| CA2795334A1 (en) | 2011-10-13 |
| WO2011124366A1 (de) | 2011-10-13 |
| JP6158077B2 (ja) | 2017-07-05 |
| JP2013523789A (ja) | 2013-06-17 |
| RU2555765C2 (ru) | 2015-07-10 |
| DE102010014290A1 (de) | 2011-10-13 |
| CN103153312B (zh) | 2015-07-22 |
| CN103153312A (zh) | 2013-06-12 |
| US20130190301A1 (en) | 2013-07-25 |
| JP6158077B6 (ja) | 2018-08-29 |
| EP2374461B1 (de) | 2016-10-26 |
| ES2612584T3 (es) | 2017-05-17 |
| RU2012147474A (ru) | 2014-05-20 |
| EP2374461A1 (de) | 2011-10-12 |
| PL2374461T3 (pl) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ma et al. | Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway | |
| Van Brummelen et al. | The potential role of resveratrol as supportive antiviral in treating conditions such as COVID-19–a formulator’s perspective | |
| US12161610B2 (en) | Method of viral inhibition | |
| KR20210035339A (ko) | 바이러스 감염을 치료하기 위한 티아졸리드 화합물 | |
| JP2025166032A (ja) | 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物 | |
| WO2021207325A1 (en) | Natural extract and their components for use in mitigating acute respiratory distress syndrome | |
| JP2008543885A (ja) | 皮膚病変治療用組成物 | |
| US20140148447A1 (en) | Agent for prophylactic and therapeutic treatment of herpes infections | |
| Pedrazini et al. | L‐lysine therapy to control the clinical evolution of pityriasis rosea: clinical case report and literature review | |
| ITRM20060163A1 (it) | Composizione spray ad uso topico per il tratamento e la prevenzione delle infezioni labiali da herpes simplex | |
| WO2015072853A1 (en) | Treatment of herpes virus infection outbreaks | |
| EP3295934B1 (en) | Antiviral pharmaceutical composition for topical use | |
| JP6830482B2 (ja) | 粘膜病変の治療のための配合物 | |
| KR20190040185A (ko) | 바이러스 감염의 치료에서 활성제로서의 키보르놀(xibornol)의 용도 |